

Short-term benefits for immunotherapy in allergic asthma

June 4 2017



(HealthDay)—Administration of allergen immunotherapy (AIT) in

patients with allergic asthma leads to lower short-term symptom and medication scores, according to a review published online May 19 in *Allergy*.

Sangeeta Dhami, M.B.B.S., from Evidence-Based Health Care in Edinburgh, U.K., and colleagues performed a systematic review to examine evidence on the effectiveness, cost-effectiveness, and safety of AIT. Data were reviewed from 98 studies.

The researchers observed a reduction in short-term symptom and medication scores, with evidence found for publication bias. No reduction was seen in short-term combined medication and symptom scores; a beneficial long-term effect was seen in one study. Subcutaneous immunotherapy correlated with improved quality of life and reduction in allergen-specific airway hyperreactivity (AHR); this was not seen for [sublingual immunotherapy](#) (SLIT). No consistent effects were seen on [asthma](#) control, exacerbations, lung function, or non-specific AHR. There was a modest increase in the risk of adverse events with AIT. Evidence on cost-effectiveness was mainly available for SLIT, which was likely to be cost-effective.

"AIT can achieve substantial reductions in short-term symptom and [medication](#) scores in [allergic asthma](#)," the authors write. "More data are needed in relation to secondary outcomes, longer-term effectiveness, and cost-effectiveness."

Several authors disclosed financial ties to the biopharmaceutical industry.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Short-term benefits for immunotherapy in allergic asthma (2017, June 4) retrieved 16 June 2024 from
<https://medicalxpress.com/news/2017-06-short-term-benefits-immunotherapy-allergic-asthma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.